Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:40 2024-05-16 am EDT			5-day change	1st Jan Change
912.9 ^DKK	-0.46%		+3.36%	+30.77%

May. 16	Health Care Flat as Momentum Wanes -- Health Care Roundup	DJ
May. 16	Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark	MT

NOVO NORDISK : Receives a Sell rating from Jefferies

May 02, 2024 at 05:34 am EDT

In a research note published by Peter Welford, Jefferies advises its customers to Sell the stock. The target price is unchanged and still at DKK 530.

Latest news about Novo Nordisk A/S

Health Care Flat as Momentum Wanes -- Health Care Roundup	May. 16	DJ
Novo Nordisk Reports Fire Incident at Under-Construction Facility in Kalundborg, Denmark	May. 16	MT
Novo Nordisk Building Under Construction at Manufacturing Hub in Denmark Hit by Fire	May. 16	MT
India's Biocon posts Q4 profit fall as higher raw material costs bite	May. 16	RE
NOVO NORDISK: FIRE AT KALUNDBORG SITE HAS NO IMPACT ON EXISTING…	May. 16	RE
Novo Nordisk building site hit by fire, Danish TV2 reports	May. 16	RE
Roche Shares Climb After Weight-Loss Drug Shows Efficacy in Early-Stage Trial -- Update	May. 16	DJ
Roche Gains as Weight-loss Injection Shows Potential in Early-stage Study	May. 16	MT
Roche shares gain on obesity drug results from early-stage trial	May. 16	RE
US Senate Committee Warns of Potential Healthcare Bankruptcy Due to Novo Nordisk's Wegovy	May. 16	MT
Health Care Up on Momentum -- Health Care Roundup	May. 15	DJ
Sector Update: Health Care Stocks Advance Late Wednesday Afternoon	May. 15	MT
Sector Update: Health Care	May. 15	MT
Novo Nordisk Weigh-Loss Drugs Could Bankrupt US Health Care, Senate Committee Report Says	May. 15	MT
UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down	May. 15	RE
Novo Nordisk Owner to Buy Controlling Stake in Single Use Support	May. 15	MT
NOVO NORDISK : UBS sticks Neutral	May. 15	ZD
Health Care Up on Improved Risk Appetite -- Health Care Roundup	May. 14	DJ
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs	May. 14	RE
Novo Nordisk's Wegovy Reduces Cardiac Events, Sustains Weight Loss, New Analysis Shows	May. 14	MT
Novo Nordisk Selling $5 Billion in Bonds to Back Catalent Deal	May. 14	MT
NOVO NORDISK : JP Morgan reaffirms its Buy rating	May. 14	ZD
NOVO NORDISK : UBS reaffirms its Neutral rating	May. 14	ZD
Stifel Lifts Novo Nordisk PT, Keeps Buy Recommendation	May. 14	MT
Novo Nordisk Plans First Bond Sale in Two Years	May. 14	MT

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Novo Nordisk CEO: Demand for Wegovy outstrips supply

May 02, 2024 at 12:36 pm EDT

NOVO NORDISK : Q1 beat; guidance upgrade but sentiment nonetheless dampened by price reductions

May 02, 2024 at 12:09 pm EDT

Novo Nordisk doesn't disappoint

January 31, 2024 at 10:48 am EST

More Strategies

Ratings for Novo Nordisk A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

912.9 DKK

Average target price

909.2 DKK

Spread / Average Target

-0.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVO NORDISK A/S	+30.77%	593B
ELI LILLY AND COMPANY	+32.36%	694B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	209B
ROCHE HOLDING AG	-3.97%	209B
AMGEN INC.	+9.27%	169B
PFIZER, INC.	+0.45%	164B

Other Pharmaceuticals

Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

NOVO NORDISK : Receives a Sell rating from Jefferies

Latest news about Novo Nordisk A/S

Chart Novo Nordisk A/S

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Novo Nordisk A/S

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals